Article
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis.
The Lancet. Oncology - 1 Oct 2024
Zhao Yi, He Ying, Wang Wei, Cai Qi, Ge Fan, Chen Zisheng, Zheng Jianqi, Zhang Yuan, Deng Hongsheng, Chen Ying, Lao Shen, Liang Hengrui, Liang Wenhua, He Jianxing
Abstract excerpt
BACKGROUND: The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial. We aimed to review the literature to comprehensively investigate the individual and comparative clinical outcomes of various ICI-based treatment strategies in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.